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Abstract
Background
Since 2013 the number of suspected adverse reactions to the quadrivalent human papillo-
mavirus (HPV) vaccine reported to the Danish Medicines Agency (DMA) has increased.
Due to the resulting public concerns about vaccine safety, the coverage of HPV vaccina-
tions in the childhood vaccination programme has declined. The aim of the present study
was to determinehealth care-seeking prior to the first HPV vaccination among females who
suspected adverse reactions to HPV vaccine.
Methods
In this registry-based case-control study, we included as cases vaccinated females with
reports to the DMA of suspected severe adverse reactions.We selected controls without
reportsof adverse reactions from the Danish vaccination registry and matched by year of
vaccination, age of vaccination, and municipality, and obtained from the Danish National
Patient Registry and The National Health Insurance ServiceRegister the history of health
care usage two years prior to the first vaccine. We analysed the data by logistic regression
while adjusting for the matching variables.
Results
The study included 316 cases who received first HPV vaccine between 2006 and 2014.
Age range of cases was 11 to 52 years, with a peak at 12 years, corresponding to the rec-
ommended age at vaccination, and another peak at 19 to 28 years, corresponding to a
catch-up programme targeting young women. Comparedwith 163,910 controls, cases had
increased care-seeking in the two years before receiving the first HPV vaccine. A multivari-
able model showed higher use of telephone/email consultations (OR 1.9; 95%CI 1.2–3.2),
physiotherapy (OR 2.1; 95%CI 1.6–2.8) and psychologist/psychiatrist (OR 1.9; 95%CI
1.3–2.7). Cases were more likely to have a diagnosis in the ICD-10 chapters of diseases of
the digestive system (OR 1.6; 95%CI 1.0–2.4), of the musculoskeletal system (OR 1.6;
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95%CI 1.1–2.2), symptoms or signs not classified elsewhere (OR 1.8; 95%CI 1.3–2.5) as
well as injuries (OR 1.5; 95%CI 1.2–1.9).
Conclusion
Before receiving the first HPV vaccination, females who suspected adverse reactions has
symptoms and a health care-seeking pattern that is different from the matched population.
Pre-vaccinationmorbidity should be taken into account in the evaluation of vaccine safety
signals.
Introduction
Vaccination against human papilloma virus (HPV) was introduced in Denmark in 2006 and a
quadrivalent HPV vaccine was included in Danish childhood vaccination programme from
2009. The primary target group is girls at the age of 12 years, but various catch-up programmes
has also been offered including a free and recommended programme for young women 19–28
years from August 2012 throughout 2013 [1]. In addition, risk based self-paid HPV vaccination
outside the target groups has been advocated by the Danish Society of Gynecology and Obstet-
rics, among others, and it is estimated that by the end of 2015 more than 0.5 million corre-
sponding to one fifth of all Danish females has been vaccinated against HPV. Notably, 151,487
(89%) of 170,630 girls born 1996–2000 has received at least one dose of HPV vaccine.
From 2013, this programme was challenged by an increasing number of reported suspected
adverse reactions [2]. Some of the reported reactions were classified as postural orthostatic
tachycardia syndrome (POTS) whereas others resembled chronic fatique syndrome including
fatigue, long-lasting dizziness, headache, and syncope [3,4]. The Danish safety signal was raised
to the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee
(PRAC) in September 2013. Furthermore, in July 2015, the European Commission requested
PRAC to assess whether there was evidence of a causal association betweenHPV vaccines and
POTS and/or complex regional pain syndrome (CRPS) as an association betweenHPV vaccine
and CRPS was raised from Japan [5]. PRAC concluded that the current evidence does not sup-
port that HPV vaccines causes CRPS or POTS [6]. In December 2015 theWHO Global Advi-
sory Committee on Vaccine Safety reported that it has not found any safety issue that would
alter its recommendation of the use of HPV vaccines, and argued that despite the difficulties in
diagnosing or fully characterizing CRPS and POTS, reviews of pre- and post-licensure data
provide no evidence that these syndromes are associated with HPV vaccination [7].
In spite of these reports, the Danish debate about safety of HPV vaccines has not been set-
tled, and vaccination rates are declining [8] as also seen in France and Japan [9,10]. It can be
argued that many of the symptoms that have been reported by vaccinated females are non-spe-
cific and will not be captured in epidemiological studies where outcomes are based on hospital
discharge diagnosis [4]. For example, headache, orthostatic intolerance, fatigue, nausea, and
cognitive dysfunctionwere the five most commonly reported symptoms among 53 girls/
women who suspected adverse events [3]. These symptoms will not be systematically recorded
in registries and databases that are used for epidemiological studies. Hence, there is a need for
additional studies to investigate the safety of HPV vaccines. In order to inform such studies, we
aimed to elucidate the Danish signal and to obtain a better understanding of the epidemiology
of the reported adverse events. The specific aim of the present study was to determine health
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care-seeking prior to the first HPV vaccination among females who suspected and reported
adverse reactions to HPV vaccine.
Methods
We conducted a registry-basedcase-control study where cases were vaccinated females with
reports of suspected severe adverse reactions, and controls were vaccinated females without
known reports of suspected adverse reactions. From the DMA we obtained a line-list of indi-
viduals with suspected adverse reactions. These events were reported by the patients, the
parents, or their doctors, and were classified as severe adverse reactions by established criteria
(mainly because the symptoms affected everyday life, e.g., not being able to attend school or
work as usual, and lead to “persistent or significant disability/incapacity”) [11]. The list was
obtained in August 2015, and included data on 322 individuals with a valid Danish Civil Regis-
try Number (CPR-number) which we needed for further linkage. These individuals repre-
sented all cases classified as severe and reported with a valid CPR-number at the time of the
data retrieval. After excluding one female from Greenland and five males, the dataset consisted
of 316 cases.
Controls were selected from the Danish vaccination registry [12] and matched with cases in
groups by year of vaccination (+/- 1 year), age at vaccination (+/- 1 year) and municipality. We
included all available controls rather than aiming at a fixed number of controls per case. We
obtained information on contacts to primary health care and hospital services in a two-year
period prior to the first HPV vaccine. Primary health care data were obtained from The
National Health Insurance ServiceRegister. Based on reimbursement codes, contacts were cat-
egorized as (1) consultations including visits at general practitioners and specialists as well as
home visits, (2) consultations by phone or e-mail, (3) laboratory analyses at a primary health
care provider or by referral, (4) any type of physiotherapy or referral to chiropractor, (5) pri-
vate specialist in psychiatry (including youth psychiatry) and psychologist, and (6) dental
treatment.
Contacts to hospitals were obtained from the National Patients Registry. We included only
main diagnoses.We parametrized diagnoses according to chapters in ICD-10 except for
Z00-Z99 which was a commonly used category that was separated according to frequency of
contacts into Z01.6 (radiological examination, not elsewhere classified), Z03-9 (observation for
suspected disease or condition, unspecified),Z30-Z39 (persons encountering health services
related to reproduction), and other contacts in this chapter.
Both for primary health care contacts and hospital diagnosis we counted one activity per
group rather than calculating the number of contacts or diagnoses, i.e., if a study subject had at
least one visit at the general practitioner’s office it would count as an exposure in that category
and any follow-up visits were not included.
We analysed the data by logistic regression while adjusting for the matching variables; this
procedure was applied as cases and controls were matched on a group basis. Due to low num-
bers, municipality was aggregated to provinces (nomenclature of territorial units for statistics
(NUTS) code 2), year of vaccination was categorized as 2006–2009, 2010, 2011, 2012, 2013,
2014–15, and age was fitted as years except 10–12, 30–39, and 40+ years that were treated as
groups due to low numbers. All these parameters were parametrized by dummy variables. For
the final multivariable model, we considered variables that were associated with being a case
(p-value< 10%). These variables were subsequently eliminated from the logistic regression
model if they were not significant at the 5% level. Excluded variables were one-by-one re-
entered in the final model and once more eliminated based on significance testing. Finally, the
significant exposures from the multivariable model were examined for statistical interaction
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with age categorised as 10–12 years (the youngest target age for the HPV vaccination pro-
gramme), 13–18 years (old girls), 19–28 (young women in the catch-up programme), and 29+
(older women). The study was notified to the Danish data protection agency under the record
number 2008-54-0474.
Results
The 316 cases had a median age of 20 years (range 11–52 years) and the 163,910 controls a
median age 19 years (range 10–52 years). Fig 1 shows a bimodal age distribution of the cases
with one peak around 12 years of age when childhood vaccinations are offered and another
19–28 years of age corresponding to the catch-up programme. The cases received the first vac-
cine between 2006 and 2014; in total 168 (53.2%) received it in 2012–2013 and 140 of these
were> 18 years and therefore likely to be part of the catch-up programme offered in those two
years.
Table 1 shows contacts at the primary health care level in the two years prior to vaccination.
Cases had increased odds of consultations by phone or e-mail and had more laboratory analy-
ses requested than controls. Furthermore, cases were more often referred to physiotherapy/chi-
ropractor and psychiatry/psychologist.
Table 2 shows that in the two years prior to vaccination there was an increased odds of diag-
nosis in several chapters of the ICD-10 system including the respiratory system, the digestive
system, the musculoskeletal system, injuries as well as factors influencing health status and
Fig 1. Age at first HPV vaccination for 316 femaleswho had suspected adverse events reported to the DanishMedicinesAgency and served
as cases for the registrybased case-control study on care-seeking prior to the first HPV vaccination.
doi:10.1371/journal.pone.0162520.g001
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contact with the health services and symptoms, signs and abnormal findings, not elsewhere
classified.
The final multivariable model, Table 3, found independent effects of use of telephone/email
consultations (Odds Ratio (OR) 1.9), physiotherapy/chiropractor (OR 2.1), and psychiatrist/
psychologist (OR 1.9). Further, cases were more likely to have a diagnosis in the chapters of dis-
eases of the digestive system (OR 1.6), of the musculoskeletal system (OR 1.6), symptoms or
signs not classified elsewhere (OR 1.8), as well as injuries (OR 1.5). In total 203 (64.2%) of cases
had one or more occurrences of the hospital diagnoses in Table 3 or had received reimburse-
ment for physiotherapy, chiropractor, psychiatry or psychologist, compared with 66,222
(40.4%) of controls.
Table 4 shows the age-stratified results. Overall, there was no effectmodification by age as
evaluated by a formal test for interaction (p-values ranging from 0.10 to 0.78, Table 4). Thus,
with the current sample size, findings were consistent across age groups. However, there was a
tendency of a stronger association between exposure and outcome in the oldest age-category.
In most exposure-categories, care-seeking tended to increase by increasing age with the notable
exception of injuries which were more common in girls than in young women. Forty two per-
cent of the cases 11–12 years of age had a hospital contact due to injuries compared with 27%
cases, Table 4.
In the national patient registry, cases had in total 1030 discharge diagnoses (mean 3.3 per
case) compared with 267,912 diagnoses among the controls (mean 1.6 per case). There were 34
diagnoses given to the 23 cases with a diagnosis of the digestive system, including haemorrhage
of anus and rectum (4 occurrences) as well as functional dyspepsia and maxillary hypoplasia (3
occurrences each), gastro-oesophageal reflux disease, irritable bowel syndrome, unspecified
functional intestinal disorder, unspecified anal fissure, and calculus of gallbladder without cho-
lecystitis (all 2 occurrences).There were 73 diagnoses given to the 38 cases with a diagnosis of
the musculoskeletal system included epicondylitis lateralis (7 occurrences), chondromalacia
patellae, pains in limb, other chronic osteomyelitis (4 occurrences each), unspecified shoulder
lesion, muscle strain, dislocation and subluxation of joint, juvenile rheumatoid arthritis, and
other psoriatic arthropathies (all 3 occurrences each). There were 99 diagnoses given to the 44
cases with a code from the R-chapter, including 47 diagnoses of abdominal and pelvic pain,
complex chronic non-malignant pain (7 occurrences), syncope and collapse (6 occurrences)
and other and unspecified symptoms and signs involving the nervous and musculoskeletal sys-
tems (7 occurrences).There were 200 diagnoses given to the 102 cases with a diagnosis from
the S00 to T14 (injuries). The most commonly reported diagnosis was sprain and strain of
ankle (18 occurrences), various contusions (44 occurrences), soar and strains of fingers, wrist
Table 1. Primary health care contacts (assessedby reimbursement codes) two year before the first HPV vaccination in 316 femaleswho reported
suspectedadverse events to the vaccine and 163,910matched controls. Denmark, 2006 to 2015. Odds ratio is adjusted for age at vaccination, year of
vaccination, and province (NUTS 2 area code).
Type of contact before first vaccination Cases Controls Odds ratio 95%CI
Number Percent Number Percent
Consultation at the office 310 98.1 157853 96.3 1.74 0.77–3.92
Consultation by phone or e-mail 299 94.6 142862 87.2 2.38 1.44–3.92
Laboratory analysis request 249 78.8 110092 67.2 1.73 1.29–2.32
Physiotherapy or related 96 30.4 20459 12.5 2.56 1.99–3.31
Psychologist, psy-chiatrist etcetera 39 12.3 9751 5.9 2.18 1.54–3.11
Dentist 134 42.4 62590 38.2 0.94 0.65–1.35
doi:10.1371/journal.pone.0162520.t001
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Table 2. Hospital contacts two year before the first HPV vaccination in 316 femaleswho reportedsuspectedadverse events to the vaccine and
163,910matched controls. Denmark, 2006 to 2015. Odds ratio is adjusted for age at vaccination, year of vaccination and province (NUTS 2 area code).
Type of contact before first vaccination (ICD10 code and interpretation) Cases Controls Odds
ratio
95%CI
Number Percent Number Percent
Z01.6, radiological examination, not elsewhere classified 68 21.5 18359 11.2 1.91 1.45–
2.53
Z03.9, observation for suspected disease or condition, unsp. 26 8.2 5660 3.5 2.18 1.45-3-
27
Z30-Z39, persons encountering health services related to reproduction 37 11.7 9413 5.7 1.35 0.92–
1.98
Z00-Z99, factors influencing health status and contact with health services, not included
above
80 25.3 21835 13.3 1.82 1.40–
2.36
A00-B99, certain infections and parasitic diseases 5 1.6 2400 1.5 1.07 0.44–
2.62
C00-D89, neoplasms, disease of the blood and blood forming organs and certain
disorders involving immunemechanisms
6 1.9 2319 1.4 0.93 0.41–
2.12
E00-E90, endocrine, nutritional and metabolic diseases 9 2.9 3368 2.1 1.18 0.60–
2.30
F00-F99,mental and behavioural disorders 15 4.8 6450 3.9 1.20 0.71–
2.03
G00-G99, the nervous system 9 2.9 2561 1.6 1.55 0.79–
3.03
H00-H59, the eye and adnexa 7 2.2 1806 1.1 1.79 0.84–
3.81
H60-H95, the ear and mastoid process 3 1.0 1483 0.9 1.01 0.32–
3.19
I00-I99, the circulatory system 3 1.0 1094 0.7 0.92 0.29–
2.92
J00-J99, the respiratorysystem 14 4.4 3958 2.4 1.81 1.05–
3.10
K00-K93, the digestive system 23 7.3 5420 3.3 2.08 1.35–
3.20
L00-L99, the skin and subcutaneous tissue 6 1.9 2555 1.6 1.14 0.50–
2.57
M00-M99, the musculoskeletal system and connective tissue 38 12.0 8516 5.2 2.28 1.62–
3.23
N00-N99, the genitourinary system 15 4.8 5875 3.6 0.93 0.55–
1.59
O00-O00, pregnancy, childbirthand the puerperium 41 13.0 11037 6.7 1.37 0.95–
1.98
P00-P96, conditions originating in the perinatal period 0 - 53 < 0.1 -
Q00-Q99, congenital malformations, deformations and chromosomal abnormalities 5 1.6 2310 1.4 1.10 0.45–
2.66
R00-R99, symptoms, signs and abnormal clinical and laboratory findings, not elsewhere
classified
44 13.9 9709 5.9 2.33 1.68–
3.22
S00-T14, injuries 102 32.3 35693 21.8 1.81 1.42–
2.30
T14-T98, other injuries, poisoning and certainother consequences of external causes not
included in S00-T14
11 3.5 3952 2.4 1.36 0.74–
2.49
X00-X90, various external causes of accidental injury 1 0.3 93 0.1 6.77 0.93–
49.45
doi:10.1371/journal.pone.0162520.t002
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or knee (21 occurrences), open wound of finger (7 occurrences) and fracture of finger (5
occurrences).
Discussion
We found that girls or women with reports of suspected adverse reactions fromHPV vaccina-
tion already before their first vaccination had a health care-seeking pattern different from a
matched population who did not report adverse events. For example, there was increased odds
of having had injuries and being in contact with physiotherapy and chiropractor. This is com-
patible with the hypothesis that many cases had high levels of physical activity before onset of
symptoms, as suggested by Brinth el al [3]. In a case-series (without a reference group) of 53
patients with possible adverse events Brinth et al. found that 67% had a high and 33% had a
moderate physical activity level before symptom onset. Five patients were competing on a
national or international level in their sport [3]. Our observation of increased number of inju-
ries, musculoskeletal complaints and referral to physiotherapy can be interpreted as an agree-
ment with their findings.
It is, however, unlikely that high physical activity can explain all our observations. Frequent
health care attendance and the increased odds of having symptoms in the R-chapter of the
ICD-10 system, including abdominal pains, syncope and other symptoms from the autonomic
nervous systemmay point towards another hypothesis namely the presence of medically unex-
plained physical symptoms coinciding with the time of vaccination. Medically unexplained
physical symptoms and somatoform disorders are among the most common causes of contacts
with health care and is particularly common among frequent health care attenders [13,14].
Because of the high prevalence, medically unexplained physical symptoms are likely to be pres-
ent in a considerable proportion of vaccinated females. The temporal associationmay, in the
mindset of the parents or the vaccinated, be linked to vaccination.
Furthermore, cases had an increased odds ratio of contact to psychologist or psychiatrist
but not an increased odds of hospital diagnoses in the F-chapter of ICD-10, mental and
behavioural disorders. The most common psychiatric diagnosis was emotionally unstable
Table 3. Finalmultivariablemodel showing health care-seeking in the two years prior to vaccination
in 316 Danish femaleswho reportedsuspected adverse events to HPV vaccination comparedwith
163,910matched controls. Care-seeking was defined as contact to primaryhealth care (from registryof
reimbursements) or hospital (from the Danish National Patient Registry) in a two-year period before the first
HPV vaccine. All estimateswere adjusted for age at vaccination, year of vaccination and province (NUTS 2
area code).
Type of contact before first HPV vaccination Multivariable odds ratio for
care-seeking
95%CI
Consultation at primaryhealth care provider by phone or e-mail 1.91 1.15–
3.16
Reimbursement of physiotherapy, chiropractor or related
treatment
2.13 1.64–
2.76
Reimbursement of psychologist, psychiatrist or related treatment 1.87 1.31–
2.66
Hospital contact, ICD-10 code K00-K93, the digestive system 1.57 1.01–
2.45
Hospital contact, ICD-10 code M00-M99, the musculoskeletal
system and connective tissue
1.56 1.09–
2.23
Hospital contact, ICD-10 code R00-R99, symptoms, signs and
abnormal clinical and laboratory findings, not elsewhere classified
1.77 1.27–
2.48
Hospital contact, ICD-10 code S00-T14, injuries 1.51 1.18–
1.93
doi:10.1371/journal.pone.0162520.t003
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Table 4. Age specific health care-seeking in the two years prior to vaccination in 316 Danish femaleswho reportedsuspectedadverse events to
HPV vaccination comparedwith 163,910matched controls. Care-seeking was defined as contact to primaryhealth care (from registryof reimburse-
ments) or hospital (from the Danish National Patient Registry) in a two-year period before the first HPV vaccine. The analyses were restricted to significant
variables from the final multivariable model, see Table 3.
Cases Controls
Type of contact before first vaccination Age at first
HPV vaccine
Number Percent Number Percent Odds
ratio*
95% CI p-value for
interactionwith
age**
Consultation at primaryhealth care provider by
phone or e-mail
10–12 years 78 86.7 39739 77.0 2.11 1.25–
3.59
0.567
13–18 years 51 94.4 23176 79.4 1.23 0.81–
1.87
19–28 years 118 98.3 77003 96.1 1.92 1.28–
2.90
29 years + 52 100.0 2944 99.2 23.54 15.21–
36.46
Reimbursement of physiotherapy, chiropractor or
related treatment
10–12 years 12 13.3 3032 5.9 1.91 1.05–
3.44
0.104
13–18 years 14 25.9 2700 9.2 1.62 0.73–
3.61
19–28 years 49 40.8 13809 17.2 1.58 0.82–
3.07
29 years + 21 40.4 918 30.9 9.95 4.73–
20.93
Reimbursement of psychologist, psychiatrist or
related treatment
10–12 years 3 3.3 520 1.0 2.54 0.81–
7.97
0.486
13–18 years 2 3.7 494 1.7 0.88 0.15–
5.36
19–28 years 27 22.5 8409 10.5 0.87 0.26–
2.93
29 years + 7 13.5 328 11.1 5.80 1.46–
22.99
ICD 10 code K00-K93, the digestive system 10–12 years 2 2.2 909 1.8 0.93 0.23–
3.76
0.782
13–18 years 2 3.7 652 2.2 1.71 0.24–
12.27
19–28 years 14 11.7 3726 4.7 2.48 0.56–
11.06
29 years + 5 9.6 133 4.5 23.32 4.41–
123.31
ICD 10 codeM00-M99, the musculoskeletal system
and connective tissue
10–12 years 4 4.4 1575 3.1 1.13 0.42–
3.05
0.629
13–18 years 4 7.4 1306 4.5 1.51 0.37–
6.12
19–28 years 23 19.2 5409 6.8 2.48 0.85–
7.30
29 years + 7 13.5 226 7.6 17.97 5.12–
63.06
ICD 10 code R00-R99, symptoms, signs and
abnormal clinical and laboratory findings, not
elsewhere classified
10–12 years 9 10.0 2052 4.0 1.95 1.00–
3.81
0.465
13–18 years 7 13.0 1220 4.2 1.62 0.59–
4.42
19–28 years 21 17.5 6210 7.8 1.07 0.48–
2.39
29 years + 7 13.5 227 7.7 9.77 3.54–
26.99
(Continued)
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personality disorder including borderline disorder but this diagnosis was not more frequent
in cases than in controls.
Further studies based on larger datasets are needed to examine whether increased care-seek-
ing is related to specific disorders in order to understand whether any specific factors may be
associated with the experience of suspected adverse events.
Notably, of the first 107 claims that were reported to The Danish Patient Compensation
Association, only three were recognized as adverse reactions and received compensation
whereas all others were dismissed. In several of the dismissed claims, the symptoms were pres-
ent before the vaccination [15].
One important strength of the study was that the assessment of care-seekingwas obtained
by an ongoing and unbiased collection of data to national registries. The figures are therefore
reliable. Also, a number of outcomes occurred at equal odds including for example physical
primary health consultations, contacts related to pregnancy and childbirths, psychiatric diag-
noses given at a hospital as well as appointment at the dentists. This suggests that the case- and
the control-groups were comparable. Furthermore, all reported estimates were adjusted for age
at vaccination, year at vaccination and place of residence.
The study is subject to some limitations. Since August 2015 when we received the data, the
number of reported possible adverse events have increased furthermore, and by the end of
2015 a total of 2019 possible adverse events have been reported to the DMA of which 823 have
been classified as severe. At the present, we do not know if the 316 cases included in our study
are representative of all reported cases. The primary health care data contained limited clinical
information that represents another limitation. The assessment of the care-seeking behaviour
to primary health care was crude and data on diagnoses and medications issued in primary
health care would have added further value to the study. Furthermore, the data from primary
health care was limited to activities that were reimbursed as part of the National Health Insur-
ance Service.We did not obtain information on activities such as self-paid contacts to psychol-
ogist or school psychologists as well as physiotherapy offered in organisations such as sports
clubs. Hence, the proportion of females with this type of care are minimum estimates.
The study was based on data prior to the first HPV vaccine and does not exclude that some
of the females who reported suspected adverse events indeed experienced reactions caused by
the vaccine. However, the study shows that the case-population as a whole was a selected
Table 4. (Continued)
Cases Controls
Type of contact before first vaccination Age at first
HPV vaccine
Number Percent Number Percent Odds
ratio*
95% CI p-value for
interactionwith
age**
ICD 10 code S00-T14, injuries 10–12 years 38 42.2 13945 27.0 1.25 0.87–
1.79
0.681
13–18 years 24 44.4 7352 25.2 1.53 0.89–
2.64
19–28 years 30 25.0 14028 17.5 1.14 0.68–
1.91
29 years + 10 19.2 368 15.6 3.95 7.42–
32.59
Note: Cases/controls included: 10–12 years: 90/51,583; 13–18 years: 54/29,205; 19–28 years: 120/80,154; 29 years +: 52/2,968.
*Odds ratio from a logistic regressionmodel adjusting for year of vaccination and province.
** Log-likelihood ratio test comparingmain effects model with a model includingmain effects and an interaction termbetween age group and care-seeking
doi:10.1371/journal.pone.0162520.t004
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population; this may in particular be the situation for those above 28 years of age. In most
cases, some symptoms were present before the start of HPV vaccination. As mentioned, 140
cases (44%) had received the vaccination in the catch-up programme 2012–13 and in total 52
(16%) were older than 28 years at first vaccination and thus outside of the official programme.
This may indicate that more perceived adverse events can be expected to be reported when the
vaccines are offered outside of the core target group, i.e., girls before onset of sexual activity.
We propose that the high vaccination-uptake in particular in the catch-up programme and
beyond by coincidence led to considerable number of temporal associations between vaccina-
tion and medically unexplained physical symptoms. Teenagers and young women have, as
seen in the control population of the present study, a higher proportion of ICD-10 diagnosis in
the K, M and R chapters of the ICD-10 system (Table 4), and therefore a catch-up programme
may have a higher risk of being challenged by the perception of adverse events than a steady
routine vaccination at 12-years old.
The observed excess morbidity and excess care seeking does not rule out that the vaccine in
certain situations may have triggered a course that resulted in deterioration of symptoms in
some individuals in a perhaps vulnerable subpopulation, and further research should address
this possible explanation. The aim was not to disentangle these and other possible trajectories;
our aim was to explore the care-seeking behaviour before the first vaccination and emphasise
that any conclusions as regards the safety of the vaccine should be taken based on an under-
standing of the characteristics of the group from which adverse events were reported.
A number of post-licensure epidemiological studies have addressed the safety of HPV vac-
cines, including the expected number of immune mediated disorders in girls 12–15 years prior
to introduction of HPV vaccination [16]. After the introduction of the HPV vaccine the risk of
a number of defined outcomes was not found to be associated with HPV vaccination in several
studies [17–19]. A large cohort study from France did not find an increased incidence of the
autoimmune disorders studied, with the exception of Guillain-Barré syndrome for which there
was a small increased risk in the HPV vaccinated girls (~1 per 100,000 vaccinated girls) [7].
Only few studies have looked at non-specific outcomes [20,21], and we hope that our study
will provide inspiration for additional epidemiological studies to address the safety of HPV
vaccines, with a strong suggestion that pre-vaccination morbidity should be taken into account
in the evaluation of safety signals.
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